GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BUE:NVS) » Definitions » Cyclically Adjusted Revenue per Share

Novartis AG (BUE:NVS) Cyclically Adjusted Revenue per Share : ARS6,257.55 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Novartis AG Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novartis AG's adjusted revenue per share for the three months ended in Mar. 2024 was ARS9,932.977. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS6,257.55 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Novartis AG's average Cyclically Adjusted Revenue Growth Rate was 1.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 0.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novartis AG was 4.30% per year. The lowest was -0.90% per year. And the median was 1.20% per year.

As of today (2024-06-09), Novartis AG's current stock price is ARS31040.00. Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ARS6,257.55. Novartis AG's Cyclically Adjusted PS Ratio of today is 4.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novartis AG was 4.53. The lowest was 2.81. And the median was 3.70.


Novartis AG Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted Revenue per Share Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 790.61 836.85 1,128.34 1,957.19 5,903.54

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,366.47 3,047.17 4,825.00 5,903.54 6,257.55

Competitive Comparison of Novartis AG's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PS Ratio falls into.



Novartis AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=9932.977/107.3549*107.3549
=9,932.977

Current CPI (Mar. 2024) = 107.3549.

Novartis AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 91.733 101.517 97.009
201409 91.035 101.247 96.527
201412 92.913 100.704 99.050
201503 87.995 100.339 94.148
201506 95.618 100.464 102.177
201509 96.298 99.785 103.603
201512 136.960 99.386 147.941
201603 143.848 99.475 155.243
201606 147.646 100.088 158.366
201609 153.342 99.604 165.274
201612 166.948 99.380 180.346
201703 152.105 100.040 163.227
201706 173.621 100.285 185.861
201709 188.561 100.254 201.918
201712 104.144 100.213 111.566
201803 191.669 100.836 204.061
201806 247.763 101.435 262.223
201809 358.420 101.246 380.048
201812 383.235 100.906 407.728
201903 382.878 101.571 404.682
201906 460.540 102.044 484.509
201909 607.809 101.396 643.531
201912 658.935 101.063 699.957
202003 688.287 101.048 731.250
202006 690.662 100.743 735.990
202009 808.706 100.585 863.140
202012 928.530 100.241 994.429
202103 1,009.691 100.800 1,075.352
202106 1,115.448 101.352 1,181.513
202109 1,159.738 101.533 1,226.243
202112 413.356 101.776 436.016
202203 1,230.099 103.205 1,279.562
202206 1,424.259 104.783 1,459.220
202209 1,374.585 104.835 1,407.628
202212 1,703.846 104.666 1,747.615
202303 2,058.807 106.245 2,080.320
202306 3,192.974 106.576 3,216.325
202309 4,078.646 106.570 4,108.705
202312 4,099.456 106.461 4,133.869
202403 9,932.977 107.355 9,932.977

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Novartis AG  (BUE:NVS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=31040.00/6257.55
=4.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novartis AG was 4.53. The lowest was 2.81. And the median was 3.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novartis AG Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (BUE:NVS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BUE:NVS) » Definitions » Cyclically Adjusted Revenue per Share
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (BUE:NVS) Headlines

From GuruFocus

Top 5 4th Quarter Trades of BUCKHEAD CAPITAL MANAGEMENT LLC

By GuruFocus Research GuruFocus Editor 02-09-2023

Top 5 2nd Quarter Trades of Moser Wealth Advisors, LLC

By GuruFocus Research GuruFocus Editor 08-03-2022